Britain, Dec. 17, 2019/PRNewswire/— Sanofi’s Cablivi ® (caplacizumab), the first nanobody therapy for the treatment of Thrombotic Thrombocytopenic Purpura (aTTP), was given the Drug Discovery of the Year 2020 award by the British Pharmacological Society at last night’s annual conference on pharmacology.
An international judging panel commended the Sanofi team for the successful transition of caplacizumab from preclinical research to acceptance as a first-class nanobody treatment, which the Society found to be a pioneering demonstration of the role of pharmacology in the discovery and production of drugs.
Caplacizumab uses innovative nanobody technologies to provide quick protection against blood clots in small blood vessels for patients with aTTP. Ablynx created Caplacizumab, which was acquired by Sanofi in 2018.
Originally, the nanobody technique was invented after discovering that camelidae had fully functional antibodies composed only of heavy chains and therefore only light chains.
Nanobodies are perfect building blocks that are lightweight, durable and readily adaptable due to their small size and special shape, resulting in guided biological therapy.
Purpura aTTP is a rare and life-threatening blood clotting disorder that can result in severe organ damage and death.
This usually occurs as a medical emergency where, without warning, unexpected complications such as heart attack and kidney failure may occur. About Drug Discovery of the Year, The British Pharmacological Society established the Drug Discovery of the Year in 2012 to highlight the crucial role played by pharmacology in the development of new medicines and to honor the contributions of the teams of scientists researching new drugs.